Private equity firm Advent International and agribusiness Wilbur-Ellis have combined their life sciences and specialty chemicals solutions businesses to form a global distribution platform with combined sales of around €3 billion (US$2.9 billion).
Caldic – a global provider of specialty ingredients and chemicals for the life sciences and industrial formulation markets with a major presence in Europe, North America and Latin America – will benefit by increasing its global presence through a merger with Connell, which is a major player in Asia-Pacific.
“Under the ownership of Advent and Wilbur-Ellis, the combined company will benefit from two strong shareholders committed to build a leading global platform offering thorough expertise in specialty ingredients and chemicals solutions and distribution in two high-growth regions: in Asia-Pacific with Connell and in Latin America with Caldic-GTM, following Caldic’s merger with GTM in March 2022,” detail the companies.
By extending Caldic and Connell’s global footprint, the merger will accelerate growth opportunities for both principals and customers and drive further investments into people, technical labs, and sites.
Together, Caldic and Connell will have operations across 43 countries, which include 75 formulation centers and application labs.
In other business developments, DSM reached an agreement in May to sell its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of €3.85 billion (US$3.94 billion).
Advent oversaw the consolidation of Caldic and GTM – a portfolio company owned by Advent – last March, in a move to grow its specialty ingredients and chemicals business. Caldic’s product portfolio includes food ingredients, specialty chemicals and functional solutions for various life sciences and industrial end markets.
Edited by Benjamin Ferrer
Source: foodingredientsfirst.com
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
